Sodium ferric gluconate complex explained

Tradename:Ferrlecit
Dailymedid:Ferrlecit
Pregnancy Us:B
Pregnancy Us Comment:[1]
Routes Of Administration:Intravenous (IV)
Atc Prefix:B03
Atc Suffix:AC
Legal Us:Rx-only
Cas Number:34089-81-1
Pubchem:76968835
Drugbank:DB09517
Chemspiderid:34989638
Unii:CC9149U2QX
Kegg:D05859
C:66
H:121
Fe:2
Na:1
O:65
Smiles:O[C@H]([C@@H](O)C(O[Na])=O)[C@H](O)[C@H](O)CO.O[C@H]([C@@H](O)C(O1)=O)[C@H](O)[C@H](O)CO.[Fe]1(OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Stdinchi:1S/5C12H22O11.C6H12O7.2Fe.Na.3O/c5*13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;/h5*4-11,13-20H,1-3H2;2-5,7-11H,1H2,(H,12,13);;;;;;/q;;;;;;2*+3;+1;3*-2/p-1/t5*4-,5-,6-,7-,8+,9-,10+,11-,12+;2-,3-,4+,5-;;;;;;/m111111....../s1
Stdinchikey:MQBDAEHWGRMADS-XNHLMZCASA-M

Sodium ferric gluconate complex, sold under the brand name Ferrlecit, is an intravenously administered iron medication for the treatment of iron deficiency anemia in adults and in children aged six years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.[2] The macromolecule has an apparent molecular weight of 289,000–440,000 Dalton.[3] [4]

The most common side effects in adults are nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps, and pain. In children the most common side effects are hypotension, headache, hypertension, tachycardia and vomiting.

Notes and References

  1. Web site: Sodium ferric gluconate complex Use During Pregnancy . Drugs.com . 16 December 2019 . 2 April 2020.
  2. Web site: Ferrlecit- sodium ferric gluconate complex injection . DailyMed . 25 September 2019 . 2 April 2020.
  3. Web site: Sodium ferric gluconate complex. www.drugbank.ca . 21 June 2020.
  4. Fishbane S, Wagner J . Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis . American Journal of Kidney Diseases . 37 . 5 . 879–83 . May 2001 . 11325667 . 10.1016/s0272-6386(05)80001-0 .